Related Experiment Video
Updated: Apr 13, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
Published on: February 21, 2011
Anticholinergic Use Is a Major Risk Factor for Dysphonia
Sunny Haft1, Douglas Farquhar2, Ryan Carey2
1Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA sunny.haft@gmail.com.
Anticholinergic medications significantly increase the risk of unexplained hoarseness (dysphonia). Taking two or more such drugs raises the odds of hoarseness by over four times, highlighting medication side effects as a key factor.
Area of Science:
- Otolaryngology
- Pharmacology
- Clinical Medicine
Background:
- Dysphonia of unclear etiology is a common clinical challenge.
- Anticholinergic medications are widely used for various conditions.
- A potential link between anticholinergic drug use and dysphonia has been hypothesized.
Purpose of the Study:
- To investigate the association between anticholinergic medication use and dysphonia of unclear etiology.
- To determine if anticholinergic drug exposure is a risk factor for hoarseness.
Main Methods:
- A cross-sectional study involving 149 patients from a tertiary care laryngology practice.
- Patients' hoarseness severity was assessed and compared with medication lists, comorbidities, age, and sex.
- Multivariate logistic regression analysis was employed to identify significant predictors.
Main Results:
- Patients taking at least one anticholinergic medication had 2.32 times higher odds of hoarseness (P=.03).
- Patients taking two or more anticholinergic medications had 4.52 times higher odds of hoarseness (P=.009).
Conclusions:
- This study identifies medication use, specifically anticholinergics, as a significant risk factor for dysphonia of unclear origin.
- Awareness of this association is crucial for accurate diagnosis and effective treatment of hoarseness.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

